A gut microbial metabolite of dietary polyphenols reverses obesity-driven hepatic steatosis
Lucas J Osborn,Karlee Schultz,William Massey,Beckey DeLucia,Ibrahim Choucair,Venkateshwari Varadharajan,Rakhee Banerjee,Kevin Fung,Anthony J Horak 3rd,Danny Orabi,Ina Nemet,Laura E Nagy,Zeneng Wang,Daniela S Allende,Belinda B Willard,Naseer Sangwan,Adeline M Hajjar,Christine McDonald,Philip P Ahern,Stanley L Hazen,J Mark Brown,Jan Claesen
DOI: https://doi.org/10.1073/pnas.2202934119
2022-11-29
Abstract:The molecular mechanisms by which dietary fruits and vegetables confer cardiometabolic benefits remain poorly understood. Historically, these beneficial properties have been attributed to the antioxidant activity of flavonoids. Here, we reveal that the host metabolic benefits associated with flavonoid consumption hinge, in part, on gut microbial metabolism. Specifically, we show that a single gut microbial flavonoid catabolite, 4-hydroxyphenylacetic acid (4-HPAA), is sufficient to reduce diet-induced cardiometabolic disease (CMD) burden in mice. The addition of flavonoids to a high fat diet heightened the levels of 4-HPAA within the portal plasma and attenuated obesity, and continuous delivery of 4-HPAA was sufficient to reverse hepatic steatosis. The antisteatotic effect was shown to be associated with the activation of AMP-activated protein kinase α (AMPKα). In a large survey of healthy human gut metagenomes, just over one percent contained homologs of all four characterized bacterial genes required to catabolize flavonols into 4-HPAA. Our results demonstrate the gut microbial contribution to the metabolic benefits associated with flavonoid consumption and underscore the rarity of this process in human gut microbial communities.